Exercise Tips

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Drugs, Rock and Roll

Drugs, Rock and Roll

Blasting music tied to drinking and drugs: study.  Full Article 

Contraception Controversy

Contraception Controversy

U.S. Catholic groups sue to block contraception mandate.  Full Article 

Emergency Plan

Emergency Plan

Exclusive: Drugmakers weigh emergency supply plan for Greece.  Full Article 

Cancer Screening

Cancer Screening

Lung cancer tests advised for some heavy smokers.  Full Article 

Diabetes Risks

Diabetes Risks

"Pre-diabetes," diabetes rising among U.S. teens.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

U.S. clears Novartis' youth high blood pressure drug

Related Topics

LOS ANGELES | Tue Dec 4, 2007 3:24am IST

LOS ANGELES (Reuters) - Novartis said on Monday that U.S. regulators approved its drug Diovan to treat high blood pressure in children and adolescents aged 6 to 16.

The drug, also known by its generic name valsartan, is an angiotensin receptor blocker.

The company said research suggests that nearly 5 percent of children and adolescents in the United States may have high blood pressure.

The condition, which had once been mainly found in adults, is striking earlier amid a surge in pediatric obesity rates.

Novartis said no relevant differences were identified between the adverse experience profile for pediatric patients aged six to 16 and that previously reported for adult patients.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.